Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. more
Time Frame | PHAR | Sector | S&P500 |
---|---|---|---|
1-Week Return | 1.31% | -2.12% | -3% |
1-Month Return | 18.49% | -3.42% | -0.73% |
3-Month Return | 19.97% | -11.13% | 2.87% |
6-Month Return | 11.52% | -5.74% | 7.17% |
1-Year Return | -18.79% | 3.97% | 25.31% |
3-Year Return | 7.95% | 1.05% | 28.38% |
5-Year Return | -45.51% | 34.37% | 81.89% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 189.33M | 228.39M | 189.85M | 205.62M | 245.32M | [{"date":"2019-12-31","value":77.18,"profit":true},{"date":"2020-12-31","value":93.1,"profit":true},{"date":"2021-12-31","value":77.39,"profit":true},{"date":"2022-12-31","value":83.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 23.92M | 25.34M | 20.18M | 17.56M | 25.21M | [{"date":"2019-12-31","value":94.41,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":79.65,"profit":true},{"date":"2022-12-31","value":69.31,"profit":true},{"date":"2023-12-31","value":99.5,"profit":true}] |
Gross Profit | 165.41M | 203.06M | 169.67M | 188.06M | 220.10M | [{"date":"2019-12-31","value":75.15,"profit":true},{"date":"2020-12-31","value":92.25,"profit":true},{"date":"2021-12-31","value":77.09,"profit":true},{"date":"2022-12-31","value":85.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 87.37% | 88.91% | 89.37% | 91.46% | 89.72% | [{"date":"2019-12-31","value":95.52,"profit":true},{"date":"2020-12-31","value":97.21,"profit":true},{"date":"2021-12-31","value":97.71,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.1,"profit":true}] |
Operating Expenses | 97.19M | 120.97M | 156.72M | 169.83M | 225.49M | [{"date":"2019-12-31","value":43.1,"profit":true},{"date":"2020-12-31","value":53.65,"profit":true},{"date":"2021-12-31","value":69.5,"profit":true},{"date":"2022-12-31","value":75.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 68.23M | 82.09M | 27.84M | 18.23M | (4.88M) | [{"date":"2019-12-31","value":83.12,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":33.91,"profit":true},{"date":"2022-12-31","value":22.21,"profit":true},{"date":"2023-12-31","value":-5.94,"profit":false}] |
Total Non-Operating Income/Expense | (26.84M) | (22.97M) | 2.58M | (4.22M) | (9.57M) | [{"date":"2019-12-31","value":-1039.67,"profit":false},{"date":"2020-12-31","value":-889.64,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-163.6,"profit":false},{"date":"2023-12-31","value":-370.55,"profit":false}] |
Pre-Tax Income | 52.29M | 47.47M | 22.03M | 14.99M | (12.01M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":90.78,"profit":true},{"date":"2021-12-31","value":42.14,"profit":true},{"date":"2022-12-31","value":28.66,"profit":true},{"date":"2023-12-31","value":-22.97,"profit":false}] |
Income Taxes | 11.74M | 6.83M | 6.76M | 1.31M | (1.46M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":58.19,"profit":true},{"date":"2021-12-31","value":57.57,"profit":true},{"date":"2022-12-31","value":11.18,"profit":true},{"date":"2023-12-31","value":-12.47,"profit":false}] |
Income After Taxes | 40.54M | 40.63M | 15.27M | 13.67M | (10.55M) | [{"date":"2019-12-31","value":99.79,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":37.59,"profit":true},{"date":"2022-12-31","value":33.65,"profit":true},{"date":"2023-12-31","value":-25.96,"profit":false}] |
Income From Continuous Operations | 36.20M | 33.03M | 13.49M | 13.67M | (10.55M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":91.27,"profit":true},{"date":"2021-12-31","value":37.26,"profit":true},{"date":"2022-12-31","value":37.78,"profit":true},{"date":"2023-12-31","value":-29.14,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 40.54M | 37.75M | 16.00M | 13.67M | (10.55M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":93.1,"profit":true},{"date":"2021-12-31","value":39.45,"profit":true},{"date":"2022-12-31","value":33.73,"profit":true},{"date":"2023-12-31","value":-26.02,"profit":false}] |
EPS (Diluted) | 0.06 | 0.16 | 0.22 | 0.46 | (0.20) | [{"date":"2019-12-31","value":13.28,"profit":true},{"date":"2020-12-31","value":33.74,"profit":true},{"date":"2021-12-31","value":48.67,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-42.52,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
PHAR | |
---|---|
Cash Ratio | 2.15 |
Current Ratio | 3.53 |
Quick Ratio | 2.76 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PHAR | |
---|---|
ROA (LTM) | -1.38% |
ROE (LTM) | -8.18% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PHAR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.47 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.53 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PHAR | |
---|---|
Trailing PE | NM |
Forward PE | 169.49 |
P/S (TTM) | 2.16 |
P/B | 2.73 |
Price/FCF | 66 |
EV/R | 1.98 |
EV/Ebitda | 74.74 |
Pharming Group NV (PHAR) share price today is $9.1
Yes, Indians can buy shares of Pharming Group NV (PHAR) on Vested. To buy Pharming Group NV from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PHAR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Pharming Group NV (PHAR) via the Vested app. You can start investing in Pharming Group NV (PHAR) with a minimum investment of $1.
You can invest in shares of Pharming Group NV (PHAR) via Vested in three simple steps:
The 52-week high price of Pharming Group NV (PHAR) is $13.2. The 52-week low price of Pharming Group NV (PHAR) is $6.65.
The price-to-earnings (P/E) ratio of Pharming Group NV (PHAR) is
The price-to-book (P/B) ratio of Pharming Group NV (PHAR) is 2.73
The dividend yield of Pharming Group NV (PHAR) is 0.00%
The market capitalization of Pharming Group NV (PHAR) is $607.38M
The stock symbol (or ticker) of Pharming Group NV is PHAR